1. Home
  2. INFU vs CCCC Comparison

INFU vs CCCC Comparison

Compare INFU & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INFU
  • CCCC
  • Stock Information
  • Founded
  • INFU 2005
  • CCCC 2015
  • Country
  • INFU United States
  • CCCC United States
  • Employees
  • INFU N/A
  • CCCC N/A
  • Industry
  • INFU Medical/Dental Instruments
  • CCCC Biotechnology: Pharmaceutical Preparations
  • Sector
  • INFU Health Care
  • CCCC Health Care
  • Exchange
  • INFU Nasdaq
  • CCCC Nasdaq
  • Market Cap
  • INFU 180.4M
  • CCCC 175.1M
  • IPO Year
  • INFU N/A
  • CCCC 2020
  • Fundamental
  • Price
  • INFU $10.21
  • CCCC $2.22
  • Analyst Decision
  • INFU Strong Buy
  • CCCC Strong Buy
  • Analyst Count
  • INFU 2
  • CCCC 4
  • Target Price
  • INFU $13.50
  • CCCC $8.50
  • AVG Volume (30 Days)
  • INFU 244.2K
  • CCCC 2.4M
  • Earning Date
  • INFU 11-06-2025
  • CCCC 10-30-2025
  • Dividend Yield
  • INFU N/A
  • CCCC N/A
  • EPS Growth
  • INFU 2168.02
  • CCCC N/A
  • EPS
  • INFU 0.24
  • CCCC N/A
  • Revenue
  • INFU $139,886,000.00
  • CCCC $34,240,000.00
  • Revenue This Year
  • INFU $9.02
  • CCCC N/A
  • Revenue Next Year
  • INFU $6.73
  • CCCC N/A
  • P/E Ratio
  • INFU $42.85
  • CCCC N/A
  • Revenue Growth
  • INFU 8.13
  • CCCC 16.55
  • 52 Week Low
  • INFU $4.61
  • CCCC $1.09
  • 52 Week High
  • INFU $11.04
  • CCCC $7.14
  • Technical
  • Relative Strength Index (RSI)
  • INFU 56.39
  • CCCC 40.78
  • Support Level
  • INFU $10.11
  • CCCC $2.09
  • Resistance Level
  • INFU $10.96
  • CCCC $2.38
  • Average True Range (ATR)
  • INFU 0.40
  • CCCC 0.23
  • MACD
  • INFU -0.09
  • CCCC -0.06
  • Stochastic Oscillator
  • INFU 34.23
  • CCCC 7.05

About INFU InfuSystems Holdings Inc.

InfuSystems Holdings Inc is a health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. INFU services are provided under a two-reportable segment. The first is Patient Services, providing the last-mile solution for clinic-to-home healthcare where the continuing treatment involves complex durable medical equipment and services. The Patient segment is comprised of Oncology, Pain Management and Wound Therapy businesses. The second, Device Solutions, supports the Patient Services platform and leverages service orientation to win incremental business from its direct payer clients. The Device segment is comprised of direct payer rentals, pump and consumable sales, and biomedical services and repair. Majority from Patient.

About CCCC C4 Therapeutics Inc.

C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.

Share on Social Networks: